Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

Clinical Infectious Diseases

Volumn 60, Issue 12, 2015, Pages 1860-1863

  Luetkemeyer, Anne F ^a   Rosenkranz, Susan L ^b   Lu, Darlene ^b   Grinsztejn, Beatriz ^c   Sanchez, Jorge ^d   Ssemmanda, Michael ^e   Sanne, Ian ^f   Mcilleron, Helen ^g   Havlir, Diane V ^a   Haas, David W ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c Funda??o Oswaldo Cruz   (Brazil)

^d IMPACTA   (Peru)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efavirenz; HIV AIDS; Pharmacogenetic; Rifampin; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; ACYLTRANSFERASE 2; CYTOCHROME P450 2B6; EFAVIRENZ; EMTRICITABINE; RIFAMPICIN; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; BENZOXAZINE DERIVATIVE; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MINIMUM PLASMA CONCENTRATION; PERU; PHARMACOGENETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS; UGANDA; BLOOD; COMPLICATION; GENETICS; METABOLISM; SOUTH AFRICA;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BENZOXAZINES; CYTOCHROME P-450 CYP2B6; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; PERU; PHARMACOGENETICS; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS; UGANDA;

EID: 84983320521     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ155     Document Type: Article

References (24)

1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, 2013.
2. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents. 2014.
3. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-91.
4. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-501.
5. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
6. Yenny, Nafrialdi, Djoerban Z, Setiabudy R. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Int J Clin Pharmacol Ther 2011; 49:162-8.
7. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012; 68:689-95.
8. Bertrand J, Verstuyft C, Chou M, et al. Dependence of efavirenz- And rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis 2014; 209:399-408.
9. Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection. J Infect Dis 2015; 211:197-205.
10. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012; 22:858-67.
11. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22:1709-17.
12. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53:863-8.
13. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G- >T) and CYP2A6 (∗9B and/or ∗17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67:427-36.
14. Court MH, Almutain F, Greenblatt D, et al. Identification of Isoniazid as a Potent Inhibitor of CYP2A6-mediated Efavirenz 7-hydroxylation in CYP2B6∗6 Genotyped Human Liver Microsomes [abstract 517]. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013.
15. Lee L, Soon GH, Chew N, Else N, Amara A, Khoo S. Differential Induction of Efavirenz Metabolism by Rifampin without and with Isoniazid in Healthy Volunteers with CYP2B6 516GG and TT Genotypes [abstract 516]. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013.
16. Haas DW, Kwara A, Richardson DM, et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 2014; 69:2175-82.
17. McIlleron HM, Schomaker M, Ren Y, et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013; 27:1933-40.
18. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
19. Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE study. Clin Infect Dis 2013; 57:586-93.
20. Human Arylamine N-Acetyltransferase Gene Nomenclature. Available at: http://nat.mbg.duth.gr. Accessed 2 December 2014.
21. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-95.
22. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25:388-90.
23. Gandhi M, Benet LZ, Bacchetti P, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009; 50:482-91.
24. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-5.